- Reuters•10 days ago
Bayer has short-listed India's Lupin and investor BC Partners as prospective buyers of medical skin cream assets in a potential 1 billion euro ($1.1 billion) deal, several people familiar with the sale told Reuters. Germany's Bayer has for more than two years sought to narrow the focus of its healthcare division and its planned $66 billion Monsanto takeover has added urgency to that drive. Bayer has, however, said a debt package and cash call would suffice to finance the Monsanto purchase, its largest ever transaction.
- Bloomberg•24 days ago
Lupin Ltd., India’s second-biggest drugmaker by market value, expects U.S. approvals for new products from its facility in the coastal state of Goa to begin again in the next two months as it addresses ...
- Reuters•4 months ago
India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said. The world's fifth-largest maker of generic drugs was the first among its Indian peers to enter the roughly $5 billion U.S. dermatology space by acquiring a controlling stake in Israel's Taro Pharmaceutical Industries Ltd in 2010.
Lupin Limited (LUPIN.NS)
NSE - NSE Delayed Price. Currency in INR
|Day's Range||1,492.25 - 1,518.45|
|52wk Range||1,280.00 - 2,096.85|
|1y Target Est||N/A|
|P/E Ratio (ttm)||26.29|
|Avg Vol (3m)||1,014,972|
|Dividend & Yield||N/A (N/A)|